TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16154698

Group type: EXPERIMENTAL
Intervention: 0.15 mg buprenorphine i.v. and placebo pill s.l.
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 0.2 mg buprenorphine s.l. and saline 0.9% i.v.
Number of subjects: 15

Group type: COMPARATOR
Intervention: saline 0.9% i.v. and placebo pill s.l.
Number of subjects: 15
Study: 12810244

Group type: EXPERIMENTAL
Intervention: Topical application of 1% methyl nicotinate (MN)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Iontophoresis of 1% acetylcholine (ACh)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Iontophoresis of 1% sodium nitroprusside (SNP)
Number of subjects: 20
Study: 10229309

Group type: EXPERIMENTAL
Intervention: Troglitazone 100mg/day
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Troglitazone 200mg/day
Number of subjects: 259

Group type: COMPARATOR
Intervention: Sulphonylurea alone
Number of subjects: 259

Group type: COMPARATOR
Intervention: All groups (including control)
Number of subjects: 259
Study: 8628470

Group type: EXPERIMENTAL
Intervention: Neuropathologic examination of surgically removed pericystic samples
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: CT imaging
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: MRI imaging
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Clinical findings
Number of subjects: 3
Study: 1333087

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (4 mg b.d. or q.i.d.)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (q.i.d.)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 3913424

Group type: EXPERIMENTAL
Intervention: Preparation A (gastropulgit) - 2 bags
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Preparation B (commercial product) - 2 bags
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 30388596

Group type: EXPERIMENTAL
Intervention: Oxandrolone (synthetic hormone analog of testosterone)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxandrolone
Number of subjects: 0
Study: 29703749

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mesenchymal stem cells (MSCs)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: c-kit+ cardiac progenitor cells (CPCs)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Combination of MSCs and CPCs
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study: 27096210

Group type: EXPERIMENTAL
Intervention: Limberg flap
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Secondary healing
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (100 healthy volunteers)
Number of subjects: 33
Study: 25567682

Group type: COMPARATOR
Intervention: Aerobic training (AG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aerobic plus resistance training (RAG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 0
Study: 24325903

Group type: EXPERIMENTAL
Intervention: Modified miniscrew‐supported Herbst appliance (EG)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional cast Herbst appliance (CG)
Number of subjects: 10
Study: 20570237

Group type: EXPERIMENTAL
Intervention: Combination intravitreal ranibizumab 0.5 mg and topically applied MMC (0.4 mg/mL for 2 min)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Topical MMC (0.4 mg/mL for 2 min) alone
Number of subjects: 10
Study: 17499993

Group type: EXPERIMENTAL
Intervention: High intensity‐individualized (HI) training group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Low intensity‐generalized (LG) training group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 16009446

Group type: EXPERIMENTAL
Intervention: Probucol (500 mg/day)
Number of subjects: 102

Group type: COMPARATOR
Intervention: No probucol treatment
Number of subjects: 102
Study: 12492585

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg/d
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study: 10663455

Group type: EXPERIMENTAL
Intervention: Intravenous dopamine infusion (2 microg/kg/min)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 27
Study: 8860788

Group type: EXPERIMENTAL
Intervention: Health promotion intervention (11 weeks of daily circuit training exercise and health lecture-discussions)
Number of subjects: 346

Group type: COMPARATOR
Intervention: Regular physical education volleyball classes
Number of subjects: 346
Study: 1310160

Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with daily cisplatin (6 mg/m² before radiotherapy)
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with weekly cisplatin (30 mg/m² on the first day of each treatment week)
Number of subjects: 331

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 331
Study: 6149738

Group type: EXPERIMENTAL
Intervention: Ketazolam
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 30560716

Group type: EXPERIMENTAL
Intervention: RAIU-Tg-based activity group (3.26 ± 1.54 GBq)
Number of subjects: 277

Group type: COMPARATOR
Intervention: Fixed activity group (3.7 GBq)
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: RAIU-Tg-based activity group
Number of subjects: 277

Group type: COMPARATOR
Intervention: Fixed activity group
Number of subjects: 277
Study: 29340765

Group type: EXPERIMENTAL
Intervention: PU endotracheal tubes with conical cuff, continuous cuff pressure measurement, continuous subglottic aspiration
Number of subjects: 103

Group type: COMPARATOR
Intervention: PVC endotracheal tubes with cylindrical cuff, intermittent cuff pressure measurement, intermittent subglottic aspiration
Number of subjects: 103
Study: 26612546

Group type: EXPERIMENTAL
Intervention: MRgFUS
Number of subjects: 30

Group type: COMPARATOR
Intervention: RFA
Number of subjects: 30
Study: 25165427

Group type: EXPERIMENTAL
Intervention: 0.075-mg palonosetron
Number of subjects: 93

Group type: COMPARATOR
Intervention: 40-mg aprepitant
Number of subjects: 93
Study: 21717516

Group type: EXPERIMENTAL
Intervention: Low-dose (72 mg-ECP/day)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: High-dose (144 mg-ECP/day)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo (PC)
Number of subjects: 97
Study: 18473194

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) iron supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Erythropoietic Stimulating Agents (ESAs)
Number of subjects: 0
Study: 17544845

Group type: EXPERIMENTAL
Intervention: (223)Ra (50 kBq/kg, 4 intravenous injections every 4 weeks)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo (4 intravenous injections every 4 weeks)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: (223)Ra
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 15846279

Group type: EXPERIMENTAL
Intervention: Carvedilol (25 mg twice daily)
Number of subjects: 3029

Group type: COMPARATOR
Intervention: Metoprolol tartrate (50 mg twice daily)
Number of subjects: 3029
Study: 12390633

Group type: EXPERIMENTAL
Intervention: Sumatriptan (6 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 10553915

Group type: EXPERIMENTAL
Intervention: Noninvasive ambulatory blood pressure monitoring
Number of subjects: 644
Study: 7790472

Group type: EXPERIMENTAL
Intervention: IgG detection using analytical isoelectrofocusing and immunoblotting methods
Number of subjects: 31
Study: 1899112

Group type: EXPERIMENTAL
Intervention: 111In-oxine
Number of subjects: 12

Group type: COMPARATOR
Intervention: 111In-tropolone
Number of subjects: 12
Study: 6625960

Group type: EXPERIMENTAL
Intervention: Active plasmapheresis
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham plasmapheresis
Number of subjects: 10
Study: 30919941

Group type: EXPERIMENTAL
Intervention: Anagrelide prolonged release (A-PR)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Reference product (standard anagrelide)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 112
Study: 29482964

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention trial
Number of subjects: 467
Study: 26813472

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 25122977

Group type: EXPERIMENTAL
Intervention: Marketed stabilized stannous fluoride (SnF2) dentifrice (Oral‐B Pro‐Expert, 0.454% SnF2 plus 0.077% NaF)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Marketed sodium fluoride (NaF)/triclosan dentifrice control (Colgate Total Advanced)
Number of subjects: 100
Study: 22433028

Group type: EXPERIMENTAL
Intervention: 30-minute rewetting period
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: 24-hour rewetting period
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (no rewetting stage)
Number of subjects: 108
Study: 20838266

Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 4640

Group type: EXPERIMENTAL
Intervention: Self-massage
Number of subjects: 4640

Group type: EXPERIMENTAL
Intervention: Medical consultation
Number of subjects: 4640

Group type: EXPERIMENTAL
Intervention: General health service utilization
Number of subjects: 4640
Study: 18205096

Group type: EXPERIMENTAL
Intervention: Fosinopril (20 mg/day)
Number of subjects: 406

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 406
Study: 15059705

Group type: EXPERIMENTAL
Intervention: Topical ofloxacin 0.3% applied four times a day for 3 days before surgery and 1 hour preoperatively
Number of subjects: 130

Group type: COMPARATOR
Intervention: Topical ofloxacin 1 hour before surgery
Number of subjects: 130
Study: 12471565

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (Artekin)
Number of subjects: 106
Study: 9707165

Group type: EXPERIMENTAL
Intervention: Budesonide (inhaled glucocorticoid)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (normal subjects)
Number of subjects: 10
Study: 9345404

Group type: EXPERIMENTAL
Intervention: Natural interferon beta (n‐IFN‐beta) 9 MIU three times a week, subcutaneously
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 60
Study: 2096345

Group type: EXPERIMENTAL
Intervention: Iontophoresis of lidocaine hydrochloride 4% solution
Number of subjects: 19
Study: 32798

Group type: EXPERIMENTAL
Intervention: Diazepam with benzyl alcohol (0.35 mg/kg diazepam, 1.1 mg/kg benzyl alcohol)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diazepam without benzyl alcohol (control group)
Number of subjects: 0
Study: 31111159

Group type: COMPARATOR
Intervention: Dietary Met/Lys ratio 0.37
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Dietary Met/Lys ratios
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: High-prolificacy sows
Number of subjects: 325
Study: 28724309

Group type: EXPERIMENTAL
Intervention: Device-guided slow breathing (DGB) for 15 minutes/day for 8 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control Group (CG) - music for 8 weeks
Number of subjects: 32
Study: 25616551

Group type: EXPERIMENTAL
Intervention: Probiotics (S. salivarius)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 23140249

Group type: EXPERIMENTAL
Intervention: Biofeedback mouse intervention (vibrates if hand is idle for more than 12 seconds)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biofeedback mouse intervention
Number of subjects: 0
Study: 22215394

Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography monitoring
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard monitoring system
Number of subjects: 24
Study: 19825327

Group type: EXPERIMENTAL
Intervention: MEL‐OD (test formulation)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Mobic (reference formulation)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Comparison of both formulations
Number of subjects: 26
Study: 17763007

Group type: EXPERIMENTAL
Intervention: Individualized home-based modified carbohydrate dietary intervention (n = 11)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Group classroom-based modified carbohydrate dietary intervention (n = 12)
Number of subjects: 23
Study: 15105212

Group type: EXPERIMENTAL
Intervention: Bispectral Index (BIS)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Alaris auditory evoked potentials (A‐AEP)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Processed electroencephalogram (pEEG)
Number of subjects: 90
Study: 11412776

Group type: EXPERIMENTAL
Intervention: Left atrial reduction (Group I)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (Group II)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Left atrial area and volume in patients with persistent atrial fibrillation (Group I)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Left atrial area and volume in patients with normal rhythm (Group I)
Number of subjects: 19
Study: 9570426

Group type: EXPERIMENTAL
Intervention: Mibefradil 50 mg and 100 mg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Mibefradil 100 mg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Mibefradil
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 7934778

Group type: EXPERIMENTAL
Intervention: Subcutaneous injection
Number of subjects: 668

Group type: EXPERIMENTAL
Intervention: Low-dose inhalation
Number of subjects: 668

Group type: EXPERIMENTAL
Intervention: High-dose inhalation
Number of subjects: 668

Group type: EXPERIMENTAL
Intervention: Scarification
Number of subjects: 668
Study: 3146727

Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Cyclosporin
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control (no drugs)
Number of subjects: 51
Study: 31402432

Group type: COMPARATOR
Intervention: NMES
Number of subjects: 36

Group type: COMPARATOR
Intervention: Photobiomodulation therapy
Number of subjects: 36
Study: 30378348

Group type: EXPERIMENTAL
Intervention: Fetal Frontomaxillary facial angle (FMFA) measurement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nuchal translucency (NT) measurement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fetal Frontomaxillary facial angle (FMFA) for diagnosing chromosomal aneuploidy
Number of subjects: 0
Study: 26850808

Group type: EXPERIMENTAL
Intervention: Therapeutic touch (TT)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 108
Study: 25633584

Group type: EXPERIMENTAL
Intervention: Moxibustion treatment before menstruation onset (Group A)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Moxibustion treatment at the onset of menstruation (Group B)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Waiting list group (Control Group C)
Number of subjects: 222
Study: 24000658

Group type: EXPERIMENTAL
Intervention: PCA with trimeperidine in combination with nefopam constant infusion
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PCA with trimeperidine in combination with nefopam bolus
Number of subjects: 60

Group type: COMPARATOR
Intervention: Isolated PCA with trimeperidine
Number of subjects: 60
Study: 20186397

Group type: EXPERIMENTAL
Intervention: Intranasally administered oxytocin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 18022165

Group type: EXPERIMENTAL
Intervention: Metformin (500 mg twice per day for 12 weeks)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 56
Study: 16531797

Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham smoking
Number of subjects: 26
Study: 12684147

Group type: COMPARATOR
Intervention: TCu 380 A
Number of subjects: 1170

Group type: EXPERIMENTAL
Intervention: TCu 380 Nul
Number of subjects: 1170

Group type: EXPERIMENTAL
Intervention: ML Cu 375 sl
Number of subjects: 1170
Study: 10719704

Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging of parotid glands
Number of subjects: 16
Study: 9211677

Group type: EXPERIMENTAL
Intervention: 1 microg of ganciclovir per hour implant
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: 2 microg of ganciclovir per hour implant
Number of subjects: 188

Group type: COMPARATOR
Intervention: Intravenous ganciclovir
Number of subjects: 188
Study: 1412113

Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone 10 mg/kg every four hours for 48 hours (group A)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone 2 mg/kg every four hours for 48 hours (group B)
Number of subjects: 82

Group type: COMPARATOR
Intervention: No intravenous corticosteroids (group C)
Number of subjects: 82
Study: 3551969

Group type: EXPERIMENTAL
Intervention: lidamidine HCl
Number of subjects: 32

Group type: COMPARATOR
Intervention: loperamide
Number of subjects: 32
Study: 31416155

Group type: EXPERIMENTAL
Intervention: Vitamin D3 20,000 IU/week
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Vitamin D3 20,000 IU/week (in subgroup with baseline 25(OH)D <50 nmol/L)
Number of subjects: 200
Study: 29136600

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 129

Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 129
Study: 27390052

Group type: EXPERIMENTAL
Intervention: MK0431A 50 mg/500 mg tablet
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: MK0431A 50 mg/850 mg tablet
Number of subjects: 24
Study: 24758075

Group type: EXPERIMENTAL
Intervention: YTR combined Methotrexate (MTX) + Leflunomide (LEF)
Number of subjects: 88

Group type: COMPARATOR
Intervention: MTX + LEF therapy
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: YTR combined MTX + LEF
Number of subjects: 88
Study: 22643324

Group type: EXPERIMENTAL
Intervention: AAQ (artesunate-amodiaquine)
Number of subjects: 12000

Group type: EXPERIMENTAL
Intervention: AAQ + AMX (artesunate-amodiaquine plus amoxicillin)
Number of subjects: 12000

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 12000
Study: 19760513

Group type: EXPERIMENTAL
Intervention: Posterolateral extravesical ureteroneocystostomy (PLEVUNC)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Anterior extravesical ureteroneocystostomy (AEVUNC)
Number of subjects: 120
Study: 18953863

Group type: EXPERIMENTAL
Intervention: Oral lamivudine (100 mg/d)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 40
Study: 16179038

Group type: EXPERIMENTAL
Intervention: Desflurane at 0.1 MAC
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Isoflurane at 0.1 MAC
Number of subjects: 25
Study: 12149106

Group type: EXPERIMENTAL
Intervention: Ramipril for 6 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ramipril for 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 0
Study: 10760037

Group type: EXPERIMENTAL
Intervention: IFN-alpha with ribavirin (1-1.2 g per day)
Number of subjects: 304

Group type: COMPARATOR
Intervention: IFN-alpha alone
Number of subjects: 304
Study: 7721636

Group type: EXPERIMENTAL
Intervention: High dose irradiation (75.6 CGE) using conformal protons
Number of subjects: 202

Group type: COMPARATOR
Intervention: Conventional dose irradiation (67.2 Gy) using photons
Number of subjects: 202
Study: 1976343

Group type: EXPERIMENTAL
Intervention: terfenadine 180 mg three times daily
Number of subjects: 18

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study: 6104133

Group type: EXPERIMENTAL
Intervention: Auscultatory percussion
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional percussion methods
Number of subjects: 28
Study: 31742459

Group type: EXPERIMENTAL
Intervention: Pro-vaccine posts
Number of subjects: 360

Group type: COMPARATOR
Intervention: Anti-vaccine posts
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Posts with actionable information/resources
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Posts with personal narrative elements
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Health-related source posts
Number of subjects: 360
Study: 28029173

Group type: EXPERIMENTAL
Intervention: Topiramate (up to 200 mg/d)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study: 25953148

Group type: EXPERIMENTAL
Intervention: Pivotal Response Treatment (PRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adult-Driven Applied Behavior Analysis (ABA) Intervention
Number of subjects: 0
Study: 23569027

Group type: EXPERIMENTAL
Intervention: 0.25% lidocaine (Group A)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 0.33% lidocaine (Group B)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 0.5% lidocaine (Group C)
Number of subjects: 120
Study: 21733570

Group type: EXPERIMENTAL
Intervention: Prednisone (0.5 mg/kg daily for 8 months)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Tamoxifen (0.5 mg/kg daily for 8 months)
Number of subjects: 40
Study: 19863338

Group type: EXPERIMENTAL
Intervention: ABVD consolidation therapy
Number of subjects: 253

Group type: COMPARATOR
Intervention: Radiation therapy (RT) consolidation
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: ABVD and RT for partial responders (PR)
Number of subjects: 253
Study: 16641168

Group type: EXPERIMENTAL
Intervention: CI-994 plus gemcitabine (CG)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Gemcitabine alone (PG)
Number of subjects: 174
Study: 14748311

Group type: EXPERIMENTAL
Intervention: Nutrition education alone
Number of subjects: 2203

Group type: EXPERIMENTAL
Intervention: Nutrition education with shelf labeling
Number of subjects: 2203

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 2203
Study: 11498678

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 0
Study: 9885072

Group type: EXPERIMENTAL
Intervention: High intensity strength training
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Moderate intensity strength training
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study: 8137469

Group type: EXPERIMENTAL
Intervention: Combination therapy of TACE followed by PEI
Number of subjects: 24

Group type: COMPARATOR
Intervention: TACE alone
Number of subjects: 24
Study: 2913250

Group type: EXPERIMENTAL
Intervention: Midazolam 0.07 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Midazolam 0.10 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Midazolam 0.13 mg/kg
Number of subjects: 0
Study: 1174050

Group type: EXPERIMENTAL
Intervention: Ethyl-3,5,6-tri-O-benzyl-D-glucofuranoside (tribenoside, Glyvenol)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5